Publication:
Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season

Simple item page
dc.contributor.authorPastor-Barriuso, Roberto
dc.contributor.authorNuñez, Olivier
dc.contributor.authorMonge Corella, Susana
dc.contributor.authorNirsevimab Effectiveness Study Collaborators
dc.contributor.authorJarrin Vera, Inmaculada
dc.contributor.funderInstituto de Salud Carlos III
dc.date.accessioned2025-02-14T09:58:38Z
dc.date.available2025-02-14T09:58:38Z
dc.date.issued2025
dc.description.peerreviewedSí
dc.description.sponsorshipThe study was funded by the Institute of Health Carlos III (on its own budget) which, at the institutional level, had no role in the study design, data collection, analysis or interpretation.
dc.description.tableofcontentsUsing real-life data from Spain between October 2023 and March 2024, the number needed to immunise (NNI) with nirsevimab and the cost to prevent one RSV hospitalisation were estimated at 90 infants (95% CI: 77–108) and 19,700 EUR for catch-up immunisation, and 41 infants (95% CI: 35–50) and 9,000 EUR for at-birth immunisation. By month of birth, NNI and cost were lowest in infants born shortly before the RSV epidemic peak, with impact decreasing gradually for earlier or later births.
dc.format.number6
dc.format.page2500040
dc.format.volume30
dc.identifier.citationPastor-Barriuso Roberto, Núñez Olivier, Monge Susana, the Nirsevimab Effectiveness Study Collaborators. Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season. Euro Surveill. 2025;30(6):2500040.
dc.identifier.doi10.2807/1560-7917.ES.2025.30.6.2500040
dc.identifier.e-issn1560-7917
dc.identifier.issn1025-496X
dc.identifier.journalEuro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin
dc.identifier.urihttps://hdl.handle.net/20.500.12105/26331
dc.language.isoeng
dc.publisherEuropean Centre for Disease Prevention and Control (ECDC)
dc.relation.publisherversionhttps://doi.org/10.2807/1560-7917.ES.2025.30.6.2500040
dc.repisalud.centroISCIII::Centro Nacional de Epidemiología (CNE)
dc.repisalud.institucionISCIII
dc.rights.accessRightsopen access
dc.rights.licenseAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectInfant
dc.subjectNirsevimab
dc.subjectEffectiveness
dc.subjectHospitalisation
dc.subjectRespiratory syncytial virus
dc.subjectImmunise
dc.subjectSpain
dc.titleInfants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublication9a976b09-a1b8-4fa5-b50d-1d747fdec304
relation.isAuthorOfPublicationeeb1202a-4061-4af1-b376-edf4643be84c
relation.isAuthorOfPublicationa0bb4f4f-11f0-487e-bf93-0b13f90057cc
relation.isAuthorOfPublication61ae00b2-33cb-424d-9b80-14b73a4f8b00
relation.isAuthorOfPublication.latestForDiscovery9a976b09-a1b8-4fa5-b50d-1d747fdec304
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublication844b1441-479c-4219-87e5-efc493160a02
relation.isPublisherOfPublication.latestForDiscovery844b1441-479c-4219-87e5-efc493160a02

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
InfantsNeededImmuniseNirsevimab_2025.pdf
Size:
187.44 KB
Format:
Adobe Portable Document Format
Download
Thumbnail Image
Name:
Supplementary_InfantsNeededImmuniseNirsevimab_2025.pdf
Size:
472.22 KB
Format:
Adobe Portable Document Format
Download

Collections

Centro Nacional de Epidemiología (CNE)